Neuroblastoma

12 trials 6 recruiting MedDRA PT
12 Registered trials
6 Recruiting
10 Unique sponsors
33 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 6
L Oncology (ATC L) 4
V Various (ATC V) 3
B Haematology (ATC B) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 10 substances
Alkylating agent 7 substances
Supportive / diluent 3 substances
CDK inhibitor 2 substances
Topoisomerase I inhibitor 2 substances
Monoclonal antibody (chimeric) 2 substances
Platinum compound 2 substances
Antimetabolite 1 substance
Radiopharmaceutical 1 substance
Topoisomerase II inhibitor 1 substance
Vinca alkaloid 1 substance
Anthracycline 1 substance
Phase III: 2 Phase II: 3 Phase I/II: 5 Phase I: 2

Filter these 12 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 12 trials

Phase III

2 trials
  • Institut Gustave Roussy Academic
    BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DINUTUXIMAB BETA; ETOPOSIDE; IRINOTECAN HYDROCHLORIDE TRIHYDRATE; MELPHALAN; TEMOZOLOMIDE; THIOTEPA; VINCRISTINE SULFATE
    2024-514917-36-00 13 countries 2024 n=880
    Recruiting
  • University Of Cologne Academic
    IMP not specified
    2024-517295-37-00 1 country n=280
    Pending

Phase II

3 trials
  • IRCCS Istituto Giannina Gaslini Academic
    ALLOGENEIC PERIPHERAL BLOOD-DERIVED HAEMATOPOIETIC STEM CELLS, TCR ALPHA/BETA+ CD19+ DEPLETED; ALLOGENEIC PERIPHERAL BLOOD-DERIVED NK CELLS CD3- CD56+; ANTI-T LYMPHOCYTE IMMUNOGLOBULIN FOR HUMAN USE, RABBIT; DINUTUXIMAB BETA; FLUDARABINE PHOSPHATE; MELPHALAN; RITUXIMAB; THIOTEPA
    2024-519089-32-02 1 country 2023 n=19
    Recruiting
  • Karolinska University Hospital Academic
    EDOTREOTIDE; L-LYSINE HYDROCHLORIDE, L-ARGININE HYDROCHLORIDE; LUTETIUM (177LU) OXODOTREOTIDE
    2023-503684-42-00 6 countries 2026 n=24 Orphan
    Ended
  • The University Of Birmingham Academic
    INDOCYANINE GREEN
    2024-514089-37-00 1 country n=30
    Pending

Phase I/II

5 trials
  • Novartis Pharma AG Commercial
    RIBOCICLIB
    2024-512095-35-00 7 countries 2022 n=49
    Ended
  • Pfizer Inc. Commercial
    CYCLOPHOSPHAMIDE MONOHYDRATE; IRINOTECAN HYDROCHLORIDE TRIHYDRATE; PALBOCICLIB; TEMOZOLOMIDE; TOPOTECAN
    2024-511975-14-00 5 countries 2022 n=29
    Ended
  • Centre Oscar Lambret Academic
    IMP not specified
    2024-513470-22-00 1 country 2019 n=63
    Ended
  • Prinses Maxima Centrum voor Kinderoncologie B.V. Academic
    CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DINUTUXIMAB BETA; DOXORUBICIN HYDROCHLORIDE; ETOPOSIDE; GLUCOSE; HUMAN ALBUMIN SOLUTION; IFOSFAMIDE; SODIUM CHLORIDE; VINCRISTINE SULFATE; WATER FOR INJECTION
    2023-509673-22-00 7 countries 2024 n=39 Orphan
    Recruiting
  • Prinses Maxima Centrum voor Kinderoncologie B.V. Academic
    SATOREOTIDE TRIZOXETAN GALLIUM (GA68)
    2024-513843-10-00 1 country 2023 n=20
    Recruiting

Phase I

2 trials
  • Universitaet Muenster Academic
    GD2IL18CART
    2022-501725-21-00 1 country 2024 n=48
    Recruiting
  • Universitaet Muenster Academic
    GD2IL18CART
    2025-521497-34-00 1 country 2025 n=20
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Universitaet Muenster Academic 2 Phase I 2
Prinses Maxima Centrum voor Kinderoncologie B.V. Academic 2 Phase I/II 2
Novartis Pharma AG Commercial 1 Phase I/II 0
Pfizer Inc. Commercial 1 Phase I/II 0
IRCCS Istituto Giannina Gaslini Academic 1 Phase II 1
Karolinska University Hospital Academic 1 Phase II 0
The University Of Birmingham Academic 1 Phase II 0
Institut Gustave Roussy Academic 1 Phase III 1
University Of Cologne Academic 1 Phase III 0
Centre Oscar Lambret Academic 1 Phase I/II 0
New trials by year
2019
1
2022
2
2023
2
2024
3
2025
1
2026
1
← All indication landscapes